Cygnus Technologies, LLC
Christine Dolan is an accomplished executive with extensive leadership experience in the life sciences and pharmaceutical industries. Currently, Christine serves as Executive Vice President and General Manager of Biologics Safety Testing at Maravai LifeSciences since November 2020, while also holding the Chief Operating Officer position at Cygnus Technologies, LLC. Previous roles include COO at Glen Research, where Christine played a pivotal role in the company’s integration into Maravai LifeSciences, and Senior Vice President of Product Development at Catalent Pharma Solutions, where contributions spanned global product development and operational oversight for numerous manufacturing sites. Earlier experience includes key positions at GE Healthcare and Amersham Health, focusing on quality control and operations management. Christine holds a Bachelor of Science degree in Biology from Lenoir-Rhyne University.
This person is not in the org chart
Cygnus Technologies, LLC
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.